Pure Global
NCT06097793

KSD-101 Therapy for EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical Trial

Kousai Bio Co., Ltd.·Phase 1·ClinicalTrials.gov·biologicalNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Nasopharyngeal Carcinoma
Drug/Device/Intervention
KSD-101
Study type
Interventional
Intervention type
biological
Sponsor & location
Primary sponsor
Kousai Bio Co., Ltd.
Location
Wuhan, China
Timeline & enrollment
Phase
Phase 1
Start date
Nov 01, 2023
End date
Dec 31, 2025
Enrollment
12 participants
Primary outcome

Safety endpoint

Summary

The main purpse of this study is to evaluate the safety of KSD-101 in patients with
 EBV-associated Nasopharyngeal Carcinoma,to evaluate the initial clinical outcomes and
 evaluate the immune response to KSD-101 for the treatment in Patients with EBV-associated
 Nasopharyngeal Carcinoma

ICD-10 classifications
Malignant neoplasm of nasopharynxMalignant neoplasm: Nasopharynx, unspecifiedMalignant neoplasm: Overlapping lesion of nasopharynxBenign neoplasm: NasopharynxMalignant neoplasm: Posterior wall of nasopharynx
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06097793
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06097793 through Pure Global AI's free database. This Phase 1 trial is sponsored by Kousai Bio Co., Ltd. and is currently Not yet recruiting. The study focuses on Nasopharyngeal Carcinoma. Target enrollment is 12 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.